- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05624216
Radiofrequency and Targeted Pressure Energy for Cellulite Reduction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the clinical efficacy and safety of radiofrequency heating and targeted pressure energy for reduction in the appearance or cellulite. The study is a prospective multi-center open-label single-arm study. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits - 1, 3 and 6 months after the last therapy visit. All of the study subjects will receive the treatment with the subject device.
At the baseline visit subject's weight will be recorded, together with hip and thigh circumference. In addition, photographs of the treated area will be taken.
The treatment administration phase will consist of four (4) treatments, delivered in 2-4 weeks. The applicator will be applied over the treatment area.
At the last therapy visit, the subject's weight will be recorded, together with hip and thigh circumference. Photographs of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire and Therapy Comfort Questionnaire to fill in.
Safety measures will include documentation of adverse events (AE). Following each treatment administration and at all of the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Coconut Grove, Florida, United States, 33133
- Dr. Busso Cosmetic Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntarily signed informed consent form
- Age ≥ 21 years
- Subject suffer from Grade 2 or Grade 3 cellulite as per Nürnberger-Muller Scale
- Subject did not experience weight change exceeding 2.5 kg (5 lb) in the preceding month
- BMI ≤ 33 kg/m2
- Women of childbearing potential are required to use birth control measures during the whole duration of the study
- Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote skin tightening and cellulite reduction during study participation
- Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation
Exclusion Criteria:
- Bacterial or viral infection, acute inflammations
- Impaired immune system
- Autoimmune disease
- Diabetes
- Herpes Simplex
- Isotretinoin in the past 12 months
- Scleroderma
- Radiation therapy
- Burns in the treatment area
- Poor healing in the treatment area
- Metal implants
- Implantable pacemaker or automatic defibrillator / cardioverter
- Ablative / non-ablative cosmetic intervention (deep peeling) in the past 3 months
- Cancer and tumor diseases
- Active collagen diseases
- Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)
- Pregnancy / nursing or IVF procedure
- Acute neuralgia and neuropathy
- Blood disorders, risk of bleeding, bleeding tissues, peptic ulcers
- Eczema
- Rosacea
- Febrile conditions
- Kidney or liver failure
- Pronounced edemas, ascites, exudates
- Sensitivity disorders in the treatment area
- Varicose veins
- Local corticosteroid therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: BTL-084 Treatment
Radiofrequency and targeted pressure energy devices for the treatment of cellulite
|
Radiofrequency and targeted pressure energy devices for the treatment of cellulite
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of cellulite severity change based on photographs before and after the study procedure according to the Cellulite Severity Scale
Time Frame: 6 months
|
Three independent evaluators will evaluate photographs for a level of cellulite severity by assigning a score according to the Cellulite Severity Scale (CSS) validated by Hexsel et al.
After follow-up visits are conducted, evaluators will be given a set of the coded photographs from each subject for an evaluation.
The Cellulite Severity Scale evaluates five key morphological features of cellulite; number of depressions, depth of depressions, clinical appearance of evident raised lesions, presence of flaccidity and the grade of cellulite.
Each item is graded from 0 to 3, allowing final classification of cellulite as mild, moderate and severe.
|
6 months
|
|
Photography evaluation according to the Global Aesthetic Improvement scale
Time Frame: 6 months
|
Three independent evaluators will evaluate photographs for a level of appearance change by assigning a score according to the Global Aesthetic Improvement scale, where the lowest possible grade is (-1), worsened state and the highest is (3) very much improved.
|
6 months
|
|
Hip and Thigh Circumference Measure
Time Frame: 6 months
|
Hip and thigh circumference measurements will be conducted at the baseline visit, after the last treatment and during all follow-up visits.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapy Comfort
Time Frame: 6 months
|
The 10-point scale will be used for evaluating the comfort during the study treatment.
Subjects will be evaluating the comfort/discomfort on a scale from 1 ("No discomfort") to 10 ("Unbearable discomfort")
|
6 months
|
|
Subject Satisfaction
Time Frame: 6 months
|
The 5-point Likert scale Satisfaction questionnaire will be used to evaluate the participant's satisfaction with the therapy outcome.
The subjects will be answering questions with possible answers varying from "Strongly disagree" to "Strongly agree"
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTL-084_100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cellulitis
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Not yet recruitingOrbital CellulitisCanada
-
McGill University Health Centre/Research Institute...CompletedCellulitis | Cellulitis of Leg | Cellulitis of ArmCanada
-
Hillel Yaffe Medical CenterUnknown
-
University of SouthamptonUniversity of Nottingham; Norfolk and Norwich University Hospitals NHS Foundation... and other collaboratorsRecruiting
-
University Hospital Plymouth NHS TrustTerminated
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUncomplicated Outpatient CellulitisCanada
-
InMode MD Ltd.CompletedCellulitis of LegUnited States
-
University of SussexCompletedCellulitis | Cellulitis of Leg | Antibiotic DurationUnited Kingdom
-
Cairo UniversityRecruitingFibrosis | Lower Limb Lymphedema | Cellulitis of LegEgypt
-
University of SalamancaCompletedLymphatic Edema | Cellulitis of Leg | Vein DiseaseSpain
Clinical Trials on BTL-084
-
AO GENERIUMRecruitingALL | B-precursor Acute Lymphoblastic Leukemia | GNR-084Russian Federation
-
Idorsia Pharmaceuticals Ltd.TerminatedHealthy SubjectsUnited Kingdom
-
BTL Industries Ltd.CompletedCircumferential Reduction | Waist Circumferential Reduction
-
William Beaumont HospitalsWithdrawnFecal IncontinenceUnited States
-
Corewell Health EastRecruitingStress Urinary IncontinenceUnited States
-
BTL Industries Ltd.CompletedCircumferential Reduction | Waist Circumferential ReductionSlovakia
-
Corewell Health EastRecruitingOveractive Bladder | Overactive Bladder Syndrome | Urinary Urgency | Urinary FrequencyUnited States
-
University Hospital, MotolCompletedAchilles TendinopathyCzechia
-
BTL Industries Ltd.CompletedFood Cravings | Self-ControlUnited States
-
Boston Urogynecology AssociatesCompletedOveractive Bladder | Stress Urinary Incontinence | Urge Incontinence | Urge and StressUnited States